- Home
- LEN vs ONC Comparison
LEN vs ONC Comparison
Compare LEN & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEN | ONC |
|---|---|---|
| Founded | 1954 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.0B | 34.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LEN | ONC |
|---|---|---|
| Price | $112.34 | $345.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | $111.46 | ★ $369.50 |
| AVG Volume (30 Days) | ★ 3.4M | 309.1K |
| Earning Date | 03-19-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.84% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.98 | 0.58 |
| Revenue | ★ $34,186,934,000.00 | $4,972,687,000.00 |
| Revenue This Year | N/A | $895.40 |
| Revenue Next Year | $5.10 | $22.04 |
| P/E Ratio | ★ $13.63 | $590.04 |
| Revenue Growth | N/A | ★ 50.43 |
| 52 Week Low | $98.42 | $196.45 |
| 52 Week High | $144.24 | $385.22 |
Technical Indicators
Market Signals| Indicator | LEN | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 57.42 |
| Support Level | $107.50 | $328.91 |
| Resistance Level | $113.94 | $353.00 |
| Average True Range (ATR) | 3.85 | 9.80 |
| MACD | -0.37 | 0.46 |
| Stochastic Oscillator | 30.85 | 74.37 |
Price Performance
Historical ComparisonAbout LEN Lennar Corporation
Lennar is one of the largest public homebuilders in the United States. The company's homebuilding operations target first-time, move-up, active adult, and luxury homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily and single-family for-rent construction and has invested in numerous housing-related technology startups.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.